MRI CONTRAST AGENT METHODS TO ASSESS TUMOR ANGIOGENESIS

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。该GCRC支持的项目需要解决NIH赠款的具体目标4：具体目标4：评估CBV，CBF和血管形态测量的潜力，以跟踪肿瘤生长，进展和对脑肿瘤患者治疗的反应。我们证明了使用新的GE/SE成像方法来获得总（GE）和微血管（SE）CBV沿着血管尺寸信息（DR 2 */DR 2）的可行性。GE CBV和比率在低级别和高级别肿瘤之间显示出显著差异，这一结果取决于对造影剂外渗效应的适当考虑。现在，我们建议获得多参数数据集（CBV，CBF，血管口径）从脑肿瘤患者随着时间的推移和放射治疗前后，并将它们与相关的免疫组织化学（IHC）标记物进行比较。我们假设每个参数在预测肿瘤血管生成、肿瘤进展和对治疗的反应中发挥独特而互补的作用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This GCRC-supported project entails addressing Specific Aim 4 of the NIH grant: Specific Aim 4: To evaluate the potential of CBV, CBF and vascular morphology measurements to track tumor growth, progression and response to treatment in brain tumor patients. We demonstrated the feasibility of using a novel GE/SE imaging method to obtain measures of total (GE) and microvascular (SE) CBV, along with vessel size information (DR2*/DR2). The GE CBV and ratio showed significant differences between low and high-grade tumors, a result dependent on the proper consideration of contrast agent extravasation effects. Now, we propose to obtain multiparameter data sets (CBV, CBF, vessel caliber) from brain tumor patients over time and before and after radiation therapy, and compare them to relevant immunohistochemical (IHC) markers. We hypothesize that each parameter will play a unique yet complementary role in predicting tumor angiogenesis, tumor progression and response to therapy.